Infected dolphins found stranded on Oʻahu shores: UH
UH researches are concerned that the infected dolphins found could be signs of a much larger problem for dolphins and whales in Hawaiʻi's waters.
UH: Urgent response required to save world's coral reefs
Response teams from UH, along with cultural practitioners for advising, responded to two dolphins found in Waimānalo on June 7 and June 8, as well as when the third dolphin was found in Waikāne on June 15.
The bacteria, Brucella ceti, can cause flu-like symptoms, neurological issues and even chronic arthritis if left untreated in humans.
'Brucella ceti can be dangerous to humans who touch infected marine mammals,' Kristi West, an associate research at UH, said. 'It is best to be cautious and avoid touching or handling stranded animals. We strongly urge the public to report any whales or dolphins in distress in the ocean or stranded on beaches.'According to UH, most carcasses are never recovered and public reporting is critical for understanding the complexities of marine mammals' health.
'Dolphins and whales are recognized sentinels of ocean health and give us signs and signals about what's happening out there,' West said. 'Three strandings within one week likely represents many more dolphins that died and were lost at sea. It raises our concern about what's happening to the animals in their ecosystem.'
Download the free KHON2 app for iOS or Android to stay informed on the latest news
Since 2000, the bacteria has been found in a variety of species of stranded dolphins and whales. Animals that tested positive for the infection showed severe brain and lung infections, while also being affected by comorbidities such as morbillivirus and hepesvirus.
The UH research team, alongside UH microbiologist Michael Norris, recently discovered a new strain of the bacteria in Hawaiian marine mammals that they say is likely the cause of the recent strandings.
To report any sightings of dead or distressed marine mammals, call the toll-free statewide NOAA Marine Wildlife Hotline at (888) 256-9840.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Jim Cramer Says He 'Was Discouraged to Get a Mixed Update from Abbott Labs'
Abbott Laboratories (NYSE:ABT) is one of the stocks that Jim Cramer shed light on. Commenting on the company's recent earnings report results, Cramer said: 'Today, in an otherwise positive market, I was discouraged to get a mixed update from Abbott Labs, medical technology company that we've long owned for the Charitable Trust… I'd say two decades. When Abbott Labs reported this morning, the… results were perfectly solid. Management tightened their full-year earnings guidance rather than raising it while also taking down their organic sales growth forecast and their operating margin outlook. wavebreakmedia/ Abbott (NYSE:ABT) is a healthcare company engaged in the research, development, manufacture, and marketing of a wide range of medical products. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
2 minutes ago
- Yahoo
Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition
Eli Lilly and Company (NYSE:LLY) is one of the . Amid carrying on new studies, the company has agreed to acquire Verve Therapeutics. Eli Lilly and Company (NYSE:LLY) is a research-driven pharmaceutical leader headquartered in Indiana. With a 150-year history, the company carries on the business of discovering, developing, manufacturing, and marketing innovative treatments across diseases like diabetes and in fields like oncology, immunology, and neuroscience. Some of the company's notable products, such as Humalog, Trulicity, Mounjaro, and Zepbound, are marketed in over 125 countries. The company is carrying on multiple studies and its latest updates include the Phase 2b clinical study titled 'A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa' and Phase 3 clinical study titled 'A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Efficacy and Safety Study of Lebrikizumab/ LY3650150 in Adults With Chronic Rhinosinusitis With Nasal Polyps on a Background Therapy With Intranasal Corticosteroids.' Along with these studies, the company has a pipeline with potential drugs capable of generating more than $1 billion in annual revenue. Amid these studies, the company has agreed to buy Verve Therapeutics Inc. for up to $1.3 billion. With this acquisition, Eli Lilly and Company (NYSE:LLY) aims to strengthen its positions in gene editing for cardiovascular conditions. With a beta of 0.44 signaling the company's resistance to market conditions, Eli Lilly and Company (NYSE:LLY) has a high anticipated 5-year EPS growth of 41.87%, making the stock a strong contender in our list. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None.
Yahoo
2 minutes ago
- Yahoo
Vektor Medical's vMap Surpasses 2,000 Procedures, Driving a New Standard in Arrhythmia Care
Milestone Highlights Rapid Hospital Adoption and Clinical Demand for Arrhythmia Insights that Improve Outcomes and Reduce Procedure Time SAN DIEGO, July 23, 2025--(BUSINESS WIRE)--Vektor Medical today announced its vMap® system has been used in more than 2,000 procedures in the U.S., a milestone that underscores its rapid adoption by electrophysiologists (EPs) and hospitals seeking to improve procedural efficiency, reduce repeat interventions, and deliver better patient outcomes. vMap, developed with AI and designed to localize both focal and fibrillation-type arrhythmias, delivers actionable insights in all four chambers of the heart in less than a minute. Clinical studies have shown that use of vMap is associated with a reduction in procedure time, which may reduce fluoroscopy time and improve safety. vMap integrates seamlessly into existing systems, making it an increasingly valuable solution for electrophysiologists seeking greater efficiency and performance without compromise. vMap is now in use at over 20 hospitals throughout the United States. "vMap has become an integral part of how I care for patients," said Dr. Anish Amin, Section Chief, Electrophysiology, OhioHealth Heart and Vascular. "It's efficient, non-invasive, and delivers insights that enhance every stage of the ablation process from planning through execution. With vMap, I can pinpoint arrhythmia sources faster with greater confidence, treat more accurately, and potentially reduce repeat interventions for patients. I'm looking forward to enrolling patients in the IMPRoVED-AF study, which will further validate the clinical impact of this technology and its potential to transform how we approach AF ablation." As adoption of pulsed field ablation (PFA) accelerates, the need for accurate, accessible data is greater than ever. vMap can enhance the impact of PFA by helping EPs identify optimal ablation targets before entering the lab and reiteratively during the procedure. With vMap's rapid, non-invasive ECG-based driver localization, physicians have more information to better target areas of interest, supporting more efficient procedures and unlocking the full potential of PFA. "This milestone represents meaningful momentum," said Robert Krummen, CEO of Vektor Medical. "With every procedure, physicians are leveraging vMap's rapid, non-invasive insights to make informed decisions and streamline care. We're seeing growing demand quarter over quarter as both physicians and hospitals look for ways to enhance efficiency and elevate patient care." The vMap system is FDA-cleared and commercially available in the United States. As clinical use continues to expand, Vektor Medical remains focused on advancing the future of arrhythmia care through clinical innovation, strategic partnerships, and physician impact. To learn more about Vektor Medical, vMap technology, or to request a clinical or strategic briefing, visit and connect with us on LinkedIn and X. About Vektor Medical Headquartered in San Diego, Vektor Medical is redefining how arrhythmias are understood and treated. The company developed vMap®, the only FDA-cleared, non-invasive technology that uses standard 12-lead ECG data to localize arrhythmia source locations across all four chambers of the heart. By helping physicians identify arrhythmia drivers more quickly and with greater accuracy, Vektor is improving outcomes, enhancing efficiencies, and accelerating access to effective treatment strategies. To learn more, visit View source version on Contacts Media Contact Stacey HolifieldLevitate(617) 233-3873vektor@